LENZ Stock Forecast & Price Target

LENZ Therapeutics is supported by a differentiated first-in-class presbyopia franchise, as VIZZ’s aceclidine-based, pupil-selective miotic mechanism delivers up to 10 hours of near-vision improvement with minimal ciliary muscle involvement and a favorable safety profile. The company is also expanding access through a new telehealth prescribing option, a 100+ person sales team, and a DTC campaign, which should help accelerate adoption after the launch initiated in October 2025 and broaden cash-pay conversions. Beyond the U.S., partnerships in Australia and New Zealand, rights in Greater China with NDA submitted and prospective approval anticipated in 1Q27, plus Europe, the Middle East, Latin America, and Asia opportunities create a meaningful global growth runway.

LENZ Therapeutics is still a pre-profit, highly dependent commercial story, with just $1.9M of revenue in 1Q26 against $45.0M of SG&A and a $41.5M net loss, underscoring how far sales lag operating costs. Although the telehealth launch and national TV campaign helped weekly mail-order prescriptions rise 94% to 1,427, management still had to rely on added access channels to address slower-than-expected ECP integration and consumer adoption barriers. Even with $220.0M in cash in 2Q26, the business remains exposed to execution risk because the outlook has already been cut, with peak U.S. VIZZ estimates reduced to $165.4M from $268.8M and peak SG&A still expected at $113.6M.